Research published in the journal Clinical Science suggests that an immune signalling protein called interleukin (IL)-26 is increased among chronic smokers with lung disease and this involvement reveals disease mechanisms of interest for developing more effective therapy for these hard-to-treat patients.
Chronic tobacco smokers have a substantially increased rate of chronic obstructive pulmonary disease (COPD), chronic bronchitis and bacterial lung infections and these disorders respond poorly to currently available therapies. This is thought to be associated with the accumulation of a type of white blood cell, called neutrophils, in their airways.
Dr Karlhans Fru Che and Professor Anders Lindén at Karolinska Institutet, Stockholm, led a team of researchers from universities in Sweden and Finland to investigate why chronic smokers with lung disease have such high levels of neutrophils. They found that an immune signalling protein called IL-26 is present at high levels in the lungs of these patients. This IL-26 is thought to be a pro-inflammatory 'neutrophil mobilizer' and has previously been found at high concentrations in patients with autoimmune conditions such as Crohn's disease and rheumatoid arthritis, as well as chronic infections such as hepatitis C, all of which are also associated with excessive accumulation of neutrophils.
"Previous research shows that the immunological alterations in the airways of chronic smokers, with or without COPD and chronic bronchitis, include an excessive accumulation of neutrophils in parallel with an enhanced frequency of bacterial infections. Our findings show for the first time that IL-26 may be involved in the mobilization of neutrophils and in the response to bacterial colonization in chronic smokers with or without COPD" commented the lead author on the study, Dr Karlhans Fru Che from Karolinska Institutet, Sweden.
Dr Che and his colleagues looked at the effects of water-soluble tobacco smoke components on human lung cells and found that the exposure triggered the cells to start producing higher than normal amounts of IL-26. They also found increased amounts of other pro-inflammatory proteins in the tobacco-exposed cells such as NF-κB, which appeared to increase in response to increased IL-26 concentrations. Abnormal regulation of NF-κB has been linked to autoimmune disease, infections and cancer in other research.
While the researchers found that IL-26 levels were higher than normal in the chronic smokers, regardless of whether they had clinically stable COPD, they also found that those who did have chronic bronchitis or growth of bacteria had higher levels of IL-26 than those who did not. Moreover, the chronic smokers with exacerbations of COPD had higher levels of IL-26 than those with clinically stable COPD.
"In a previous study, we showed that IL-26 is released by a bacterial compound in healthy human airways and that it enhances the chemotactic response of neutrophils. By now showing that IL-26 is involved in the excessive mobilization of neutrophils in chronic smokers with or without COPD and chronic bronchitis, we strengthen the evidence that this cytokine bears potential as a target for monitoring of and therapeutic intervention in airway disorders characterized by neutrophilic inflammation. However, more studies are needed to improve the understanding of the more precise mechanisms of action of IL-26 before this cytokine can be targeted in clinical trials" explained Dr Che.
The researchers believe their work indicates that IL-26 is a promising target to monitor lung disease risk or burden in chronic smokers and that this knowledge could help develop more effective therapies for this difficult-to-treat group in the future. However, they acknowledge that further work is needed to confirm this.
"Our findings position IL-26 as a promising molecular target that may help improve our understanding of the pathogenic mechanisms behind pulmonary morbidities in chronic tobacco smokers. This knowledge may prove useful for developing new diagnostic tools and criteria as well as for monitoring of disease over time. In a longer perspective, this knowledge may even prove useful for developing new therapy against tobacco-related lung diseases such as COPD, chronic bronchitis and, perhaps, against repeated bacterial infections in the airways." commented Dr Che.
Professor Ilja Striz, Associate Editor of Clinical Science commented "The pathogenesis of chronic obstructive pulmonary disease (COPD) in chronic tobacco smokers is associated with an excessive accumulation of neutrophils in the airways. Results of this collaborative study of authors from Sweden and Finland show that interleukin-26 (IL-26), a neutrophil-mobilizing cytokine, is increased in the airways of chronic smokers with or without COPD. Upregulation of IL-26 in the airways in response to tobacco smoke represents a novel mechanism by which neutrophil recruitment to the lung is regulated and emerges as a new promising molecular target."
###
Information for Editors: For more information, to request a copy of the paper or to request interviews or author contact details please contact as a first port of call:
Anastasia Stefanidou,
Communications Officer,
Biochemical Society & Portland Press,
T +44 (0)20 7685 2429 (Mon-Fri)
M +44 (0)7773 037874
[email protected] or [email protected]
To arrange interviews with Karlhans Che please contact:
Karlhans Che, PhD.
Unit for Lung and Airway Research, Institute of Environmental Medicine,
Karolinska Institutet, PO Box 210, SE-171 77 Stockholm, Sweden
Tel.: +46 (0) 7367 59503
Email: [email protected]
The paper will be published in Clinical Science and will be available at this link after publication: https://doi.org/10.1042/CS20180057. Clinical Science is owned by the Biochemical Society, and published by Portland Press.
The study was carried out as a collaboration between Lund University, University of Gothenburg, University Hospital and University of Oulu, Karolinska University Hospital and the Karolinska Institutet.
The study was funded by the Foundation Olle Bohlin, the Karolinska Institutet, King Gustaf V and Queen Victoria's Foundation of Freemasons, Stockholm City Council (ALF No. 20140309 & No. 20150061), Swedish Heart-Lung Foundation (No. 20150303, HLF20160427, HLF20120801, No. 20130293, No. 20080462 & HLF20130486), Swedish Research Council (No. 2016-01653 & K2014-58X-22502-01-5), the Region Västra Götaland (LUA No. 141851), the King Oscar II Jubilee Foundation, the Mats Kleberg Foundation, the Hesselmans Foundation, Swedish Governmental Agency for Innovation Systems (VINNOVA), the Swedish Foundation for Strategic Research (SSF) (No. A514 06/0123), European Union (EU) Fp6 Marie Curie International Reintegration Grant (IRF) (No. IRG_046516), Evy and Gunnar Sandberg Foundation (No. 2008/3623), Royal Physiographic Society in Lund (No. 32779, 34549, 36139), Region Skåne Research Funds, and Regional Funding from Skåne County Council (ALF No. 2014/354).
Portland Press Community owned, Portland Press works in partnership with active researchers and information professionals to share knowledge and advance the life sciences. As an independent Society publisher we are a strong voice, advocating for our international community and for molecular life science research.
The Biochemical Society works to promote the molecular biosciences; facilitating the sharing of expertise, supporting the advancement of biochemistry and molecular biology and raising awareness of their importance in addressing societal grand challenges.
Media Contact
Anastasia Stefanidou
[email protected]
@biochemsoc
http://www.biochemistry.org
http://dx.doi.org/10.1042/CS20180057
